{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:27:14Z","timestamp":1777627634288,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijcard.2013.04.149","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T06:15:16Z","timestamp":1368080116000},"page":"633-635","source":"Crossref","is-referenced-by-count":5,"title":["Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: Insights from the FDA reports"],"prefix":"10.1016","volume":"168","author":[{"given":"James J.","family":"DiNicolantonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2013.04.149_bb0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.04.149_bb0025","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ijcard.2013.04.149_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000342085","article-title":"Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO","volume":"123","author":"Serebruany","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2013.04.149_bb0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2012.09.113","article-title":"Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates","volume":"164","author":"DiNicolantonio","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2013.04.149_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijcard.2012.11.110","article-title":"Exploring the reduction in myocardial infarction in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?","volume":"165","author":"DiNicolantonio","year":"2013","journal-title":"Int J Cardio"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313007961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313007961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:25:08Z","timestamp":1539649508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527313007961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0167527313007961"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2013.04.149","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}